PMID- 28734907 OWN - NLM STAT- MEDLINE DCOM- 20181113 LR - 20220330 IS - 1573-2509 (Electronic) IS - 0920-9964 (Linking) VI - 193 DP - 2018 Mar TI - Predicting relapse in schizophrenia: Is BDNF a plausible biological marker? PG - 263-268 LID - S0920-9964(17)30398-5 [pii] LID - 10.1016/j.schres.2017.06.059 [doi] AB - Understanding the biological processes that underlie why patients relapse is an issue of fundamental importance to the detection and prevention of relapse in schizophrenia. Brain Derived Neurotrophic Factor (BDNF), a facilitator of brain plasticity, is reduced in patients with schizophrenia. In the present study, we examined whether decreases in plasma BDNF levels could be used as a biological predictor of relapse in schizophrenia. A total of 221 patients were prospectively evaluated for relapse over 30months in the Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared to Injectables: eValuating Efficacy (PROACTIVE) study. Serial blood samples were collected at a maximum of 23 time points during the 30-month trial and BDNF levels were measured in plasma samples by ELISA. Receiver Operating Characteristic (ROC) curve analysis indicated that BDNF was not a significant predictor of relapse, hospitalization or exacerbation. Regardless of treatment group (oral second generation antipsychotic vs. long-acting injectable risperidone microspheres), baseline BDNF value did not differ significantly between those who experienced any of the adverse outcomes and those who did not. While contrary to the study hypothesis, these robust results offer little support for the use of plasma BDNF alone as a biomarker to predict relapse in schizophrenia. CI - Copyright (c) 2017. Published by Elsevier B.V. FAU - Pillai, Anilkumar AU - Pillai A AD - Medical College of Georgia, Augusta University, Augusta, GA, United States. FAU - Schooler, Nina R AU - Schooler NR AD - SUNY Downstate Medical Center, Brooklyn, NY, United States. FAU - Peter, Diya AU - Peter D AD - Medical College of Georgia, Augusta University, Augusta, GA, United States. FAU - Looney, Stephen W AU - Looney SW AD - Medical College of Georgia, Augusta University, Augusta, GA, United States. FAU - Goff, Donald C AU - Goff DC AD - Nathan Kline Institute, Orangeburg, NY, United States. FAU - Kopelowicz, Alexander AU - Kopelowicz A AD - David Geffen School of Medicine at University of California-Los Angeles, CA, United States. FAU - Lauriello, John AU - Lauriello J AD - University of Missouri, Columbia School of Medicine, Columbia, MO, United States. FAU - Manschreck, Theo AU - Manschreck T AD - Harvard Medical School, Corrigan MH Center, Beth Israel Deaconess Medical Center, Boston, MA, United States. FAU - Mendelowitz, Alan AU - Mendelowitz A AD - Feinstein Institute for Medical Research, The Zucker Hillside Hospital, Glen Oaks, NY, United States. FAU - Miller, Del D AU - Miller DD AD - University of Iowa Carver College of Medicine, Iowa City, IA, United States. FAU - Severe, Joanne B AU - Severe JB AD - National Institute of Mental Health, Bethesda, MD, United States. FAU - Wilson, Daniel R AU - Wilson DR AD - The University of Florida College of Medicine-at Jacksonville, Jacksonville, FL, United States. FAU - Ames, Donna AU - Ames D AD - David Geffen School of Medicine at University of California-Los Angeles, CA, United States. FAU - Bustillo, Juan AU - Bustillo J AD - University of New Mexico School of Medicine, Albuquerque, NM, United States. FAU - Kane, John M AU - Kane JM AD - Feinstein Institute for Medical Research, The Zucker Hillside Hospital, Glen Oaks, NY, United States. FAU - Buckley, Peter F AU - Buckley PF AD - Medical College of Georgia, Augusta University, Augusta, GA, United States; School of Medicine, Virginia Commonwealth University, Richmond, VA, United States. Electronic address: peter.buckley@vcuhealth.org. LA - eng GR - U01 MH070011/MH/NIMH NIH HHS/United States PT - Journal Article PT - Multicenter Study PT - Research Support, N.I.H., Extramural DEP - 20170719 PL - Netherlands TA - Schizophr Res JT - Schizophrenia research JID - 8804207 RN - 0 (Antipsychotic Agents) RN - 0 (Brain-Derived Neurotrophic Factor) SB - IM MH - Adult MH - Antipsychotic Agents/therapeutic use MH - Brain-Derived Neurotrophic Factor/*metabolism MH - Drug Delivery Systems MH - Female MH - Humans MH - Male MH - Middle Aged MH - Predictive Value of Tests MH - Prospective Studies MH - Psychiatric Status Rating Scales MH - Psychotic Disorders/*blood/drug therapy MH - ROC Curve MH - Recurrence MH - Schizophrenia/*blood/*diagnosis/drug therapy MH - United States OTO - NOTNLM OT - BDNF OT - Clinical trial OT - Relapse OT - Schizophrenia EDAT- 2017/07/25 06:00 MHDA- 2018/11/14 06:00 CRDT- 2017/07/24 06:00 PHST- 2017/03/16 00:00 [received] PHST- 2017/06/27 00:00 [revised] PHST- 2017/06/28 00:00 [accepted] PHST- 2017/07/25 06:00 [pubmed] PHST- 2018/11/14 06:00 [medline] PHST- 2017/07/24 06:00 [entrez] AID - S0920-9964(17)30398-5 [pii] AID - 10.1016/j.schres.2017.06.059 [doi] PST - ppublish SO - Schizophr Res. 2018 Mar;193:263-268. doi: 10.1016/j.schres.2017.06.059. Epub 2017 Jul 19.